Prasanth Reddy
Overview
Explore the profile of Prasanth Reddy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
438
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mankan A, Shankar A, Limaye S, Ajaikumar B, Nachane P, Singh N, et al.
JCO Glob Oncol
. 2024 Jun;
10:e2300405.
PMID: 38870438
Executing global clinical trials for cancer is a long, expensive, and complex undertaking. While selecting countries global studies, sponsors must consider several aspects including patient pool, quality of trained investigators,...
2.
Haberberger J, Pegram W, Britt N, Schiavone K, Severson E, Sharaf R, et al.
Oncologist
. 2023 Aug;
29(1):e47-e58.
PMID: 37619245
The authors present a cohort of 661 young adult glioblastomas diagnosed using 2016 WHO World Health Organization Classification of Tumors of the Central Nervous System, utilizing comprehensive genomic profiling (CGP)...
3.
Hogg G, Severson E, Cai L, Hoffmann H, Holden K, Fitzgerald K, et al.
Cancer Genet
. 2023 Aug;
278-279:38-49.
PMID: 37586297
Myeloid neoplasms represent a broad spectrum of hematological disorders for which somatic mutation status in key driver genes is important for diagnosis, prognosis and treatment. Here we summarize the findings...
4.
Severson E, Achyut B, Nesline M, Pabla S, Previs R, Kannan G, et al.
J Mol Diagn
. 2023 May;
25(7):454-466.
PMID: 37164276
NRG1 gene fusions are rare, therapeutically relevant, oncogenic drivers that occur across solid tumor types. To understand the landscape of NRG1 gene fusions, 4397 solid tumor formalin-fixed, paraffin-embedded samples consecutively...
5.
Harvey M, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, et al.
JCO Precis Oncol
. 2022 Jan;
5:1611-1624.
PMID: 34994647
Purpose: This study assessed the economic impact of increased use of comprehensive genomic profiling (CGP) versus conventional testing strategies among patients with advanced non-small-cell lung cancer (aNSCLC) from a US...
6.
Huang R, Severson E, Haberberger J, Duncan D, Hemmerich A, Edgerly C, et al.
Pathol Oncol Res
. 2021 Jul;
27:592997.
PMID: 34257540
Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion...
7.
Jacob J, Necchi A, Grivas P, Hughes M, Sanford T, Mollapour M, et al.
Urol Oncol
. 2021 Jul;
39(10):731.e1-731.e15.
PMID: 34215504
Background: Carcinoma of the urethra (UrthCa) is an uncommon Genitourinary (GU) malignancy that can progress to advanced metastatic disease. Methods: One hundred twenty-seven metastatic UrthCa underwent hybrid capture-based comprehensive genomic...
8.
Carcamo B, Bista R, Wilson H, Reddy P, Pacheco J
J Pediatr Hematol Oncol
. 2021 Jun;
43(5):e718-e722.
PMID: 34157012
Most inflammatory myofibroblastic tumors (IMTs) harbor ALK fusions but oncogene fusions involving ROS1, RET, NTRK, and PDGFR also occur. The recognition that most IMTs harbor receptor tyrosine kinase fusions has...
9.
Ramkissoon L, Pegram W, Haberberger J, Danziger N, Lesser G, Strowd R, et al.
Front Neurol
. 2020 Nov;
11:544680.
PMID: 33192972
Despite advances in systemic therapies for solid tumors, the development of brain metastases remains a significant contributor to overall cancer mortality and requires improved methods for diagnosing and treating these...
10.
Rankin A, Johnson A, Roos A, Kannan G, Knipstein J, Britt N, et al.
Oncologist
. 2020 Sep;
26(1):e153-e163.
PMID: 32918774
RAF family protein kinases signal through the MAPK pathway to orchestrate cellular proliferation, survival, and transformation. Identifying BRAF alterations in pediatric cancers is critically important as therapeutic agents targeting BRAF...